GIANT: a prospective, multicenter, real-world study on the effectiveness, safety, and tolerability of atogepant in migraine patients with multiple therapeutic failures

Table 5 Treatment-emergent adverse event (TEAEs) emerged among the 183 subjects enrolled (safety population

	N (%)	Grade^a (according to Hartwig SC, et al [17])
Patients with TEAEs	10/183 (5.5)	I	II	III
• Constipation • Nausea • Constipation and nausea • Hypertension	5 (2.7) 2 (1.1) 2 (1.1) 1 (0.5)	2 1	3 1 1	2
Discontinuations due to TEAEs	3 (1.6)^b

^aGrade I: the adverse event occurs without requiring any adjustment to the current pharmacological therapy; Grade II: the adverse event necessitates discontinuation of the drug or adjustment of its dosage. No supplementary treatment or antidote is required; Grade III: the adverse event necessitates discontinuation of the suspected drug, whether by interruption, suspension, or modification of the therapeutic regimen, and may warrant the administration of a specific antidote
^bTwo subjects discontinued the treatment due to severe nausea and constipation, which were considered treatment-related. One patient discontinued due to hypertension, which was considered unrelated to the treatment

ISSN: 1129-2377